{"id":"chlortalidone","rwe":[{"pmid":"30000622","year":"2006","title":"Chlorthalidone.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"39484134","year":"2024","title":"Efficacy and Safety of Chlortalidone and Hydrochlorothiazide in Prevention of Cardiovascular Diseases.","finding":"","journal":"Reviews in cardiovascular medicine","studyType":"Clinical Study"},{"pmid":"39243877","year":"2024","title":"Prevention of Heart Failure in Hypertension-the Role of Coronary Heart Disease Events Treated With Versus Without Revascularization: The ALLHAT Study.","finding":"","journal":"The American journal of cardiology","studyType":"Clinical Study"},{"pmid":"39067499","year":"2024","title":"Knowing the minimal detectable dose can facilitate the interpretation of a hair test result: Case example with chlortalidone.","finding":"","journal":"Clinica chimica acta; international journal of clinical chemistry","studyType":"Clinical Study"},{"pmid":"38743262","year":"2024","title":"Cu/Co Bimetallic Carbon Catalyst as a Highly Efficient Promoter for Reactive Dyes Degradation with PMS.","finding":"","journal":"Langmuir : the ACS journal of surfaces and colloids","studyType":"Clinical Study"}],"tags":[{"label":"Thiazide-like Diuretic","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Carbonic anhydrase 7","category":"target"},{"label":"CA7","category":"gene"},{"label":"CA12","category":"gene"},{"label":"CA5B","category":"gene"},{"label":"C03BA04","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Active","category":"status"},{"label":"Edema","category":"indication"},{"label":"Hypertensive disorder","category":"indication"},{"label":"Peripheral Edema due to Chronic Heart Failure","category":"indication"},{"label":"Pulmonary Edema due to Chronic Heart Failure","category":"indication"},{"label":"Approved 1960s","category":"decade"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Diuretics","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"},{"label":"Natriuretic Agents","category":"pharmacology"},{"label":"Sodium Chloride Symporter Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":259.221,"date":"","count":262,"signal":"Hyponatraemia","source":"DrugCentral FAERS","actionTaken":"Reported 262 times (LLR=259)"},{"llr":140.904,"date":"","count":174,"signal":"Hypokalaemia","source":"DrugCentral FAERS","actionTaken":"Reported 174 times (LLR=141)"},{"llr":112.028,"date":"","count":40,"signal":"Renal artery stenosis","source":"DrugCentral FAERS","actionTaken":"Reported 40 times (LLR=112)"},{"llr":101.034,"date":"","count":25,"signal":"Renal cyst haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=101)"},{"llr":89.762,"date":"","count":80,"signal":"Presyncope","source":"DrugCentral FAERS","actionTaken":"Reported 80 times (LLR=90)"},{"llr":89.54,"date":"","count":41,"signal":"Meningitis aseptic","source":"DrugCentral FAERS","actionTaken":"Reported 41 times (LLR=90)"},{"llr":88.713,"date":"","count":21,"signal":"SARS-CoV-2 antibody test positive","source":"DrugCentral FAERS","actionTaken":"Reported 21 times (LLR=89)"},{"llr":85.75,"date":"","count":23,"signal":"Intraductal papillary mucinous neoplasm","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=86)"},{"llr":80.14,"date":"","count":18,"signal":"Vena cava injury","source":"DrugCentral FAERS","actionTaken":"Reported 18 times (LLR=80)"},{"llr":76.013,"date":"","count":20,"signal":"Abdominal wall haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 20 times (LLR=76)"},{"llr":74.91,"date":"","count":26,"signal":"Rectal prolapse","source":"DrugCentral FAERS","actionTaken":"Reported 26 times (LLR=75)"},{"llr":72.295,"date":"","count":16,"signal":"Vascular anastomotic haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=72)"},{"llr":67.516,"date":"","count":15,"signal":"Perineal cyst","source":"DrugCentral FAERS","actionTaken":"Reported 15 times (LLR=68)"},{"llr":66.122,"date":"","count":25,"signal":"Carotid arteriosclerosis","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=66)"},{"llr":63.537,"date":"","count":25,"signal":"Delayed graft function","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=64)"}],"drugInteractions":[{"url":"/drug/dofetilide","drug":"dofetilide","action":"Avoid combination","effect":"May interact with Chlorthalidone, Dofetilide","source":"DrugCentral","drugSlug":"dofetilide"},{"url":"/drug/lithium","drug":"lithium","action":"Avoid combination","effect":"May interact with Chlorthalidone, Lithium","source":"DrugCentral","drugSlug":"lithium"}],"commonSideEffects":[],"contraindications":["Acute nephropathy","Acute pancreatitis","Acutely Decompensated HF Requiring Parenteral Inotropic Therapy","Anaphylaxis","Anuria","Asthma","Atrioventricular block","Calculus in biliary tract","Cardiogenic shock","Cerebrovascular disease","Chronic disease of respiratory system","Chronic heart failure","Chronic myocardial ischemia","Complete atrioventricular block","Conduction disorder of the heart","Depressive disorder","Diabetes mellitus type 1","Diabetes mellitus type 2","Electroconvulsive therapy","End stage renal disease","Epilepsy","First Degree Atrioventricular Heart Block","Gout","Hepatic failure","Hypercalcemia"],"specialPopulations":{"Pregnancy":"May cause fetal harm. Available data over decades from observational studies and reports with chlorthalidone use in pregnant women have not identified drug-associated risk of major birth defects or miscarriage. However, adverse fetal outcomes, including fetal or neonatal jaundice, thrombocytopenia, hypoglycemia, and electrolyte abnormalities have been reported following maternal use of thiazide diuretics. Chlorthalidone should not be used as first-line therapy to treat hypertension in pregnancy. Advise pregnant women of the potential risk to fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is to 4% and 15 to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, pr","Geriatric use":"No overall difference in responses versus younger patients but care should be taken in dose selection in patients with impaired renal function.","Paediatric use":"Safety and effectiveness in children has not been established.","Renal impairment":"Care should be taken in dose selection in patients with impaired renal function."}},"trials":[],"aliases":["Hygroton, Thalitone, Thiazide diuretic"],"patents":[{"source":"FDA Orange Book via DrugCentral","expires":"2031-07-01","territory":"US","patentNumber":"9387249"},{"source":"FDA Orange Book via DrugCentral","expires":"2030-02-04","territory":"US","patentNumber":"9169238"},{"source":"FDA Orange Book via DrugCentral","expires":"2028-03-26","territory":"US","patentNumber":"9066936"},{"source":"FDA Orange Book via DrugCentral","expires":"2025-05-22","territory":"US","patentNumber":"7157584"},{"source":"FDA Orange Book via DrugCentral","expires":"2025-01-07","territory":"US","patentNumber":"7572920"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Chlortalidone","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:00:01.752706+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T02:00:01.752607+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:00:08.981257+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chlortalidone","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:00:09.349678+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Thiazide-sensitive sodium-chloride cotransporter inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:00:10.408093+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1055/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:00:10.067636+00:00"}},"allNames":"combipres","offLabel":[],"synonyms":["clortalidone","phthalamudine","chlorphthalidolone","chlorthalidone","chlorthalidon","chlortalidone"],"timeline":[{"date":"1960-04-07","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"approvals":[{"date":"1960-04-07","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Combipres","ecosystem":[{"indication":"Edema","otherDrugs":[{"name":"acetazolamide","slug":"acetazolamide","company":"Teva Branded Pharm"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"bumetanide","slug":"bumetanide","company":""},{"name":"chlorothiazide","slug":"chlorothiazide","company":"Oak Pharms Akorn"}],"globalPrevalence":null},{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null},{"indication":"Peripheral Edema due to Chronic Heart Failure","otherDrugs":[{"name":"acetazolamide","slug":"acetazolamide","company":"Teva Branded Pharm"},{"name":"bumetanide","slug":"bumetanide","company":""},{"name":"chlorothiazide","slug":"chlorothiazide","company":"Oak Pharms Akorn"},{"name":"ethacrynic acid","slug":"ethacrynic-acid","company":"Aton"}],"globalPrevalence":64000000},{"indication":"Pulmonary Edema due to Chronic Heart Failure","otherDrugs":[{"name":"bumetanide","slug":"bumetanide","company":""},{"name":"chlorothiazide","slug":"chlorothiazide","company":"Oak Pharms Akorn"},{"name":"ethacrynic acid","slug":"ethacrynic-acid","company":"Aton"},{"name":"furosemide","slug":"furosemide","company":"Sanofi Aventis Us"}],"globalPrevalence":64000000}],"mechanism":{"target":"Carbonic anhydrase 7","novelty":"Follow-on","targets":[{"gene":"CA7","source":"DrugCentral","target":"Carbonic anhydrase 7","protein":"Carbonic anhydrase 7"},{"gene":"CA12","source":"DrugCentral","target":"Carbonic anhydrase 12","protein":"Carbonic anhydrase 12"},{"gene":"CA5B","source":"DrugCentral","target":"Carbonic anhydrase 5B, mitochondrial","protein":"Carbonic anhydrase 5B, mitochondrial"},{"gene":"CA9","source":"DrugCentral","target":"Carbonic anhydrase 9","protein":"Carbonic anhydrase 9"},{"gene":"CA4","source":"DrugCentral","target":"Carbonic anhydrase 4","protein":"Carbonic anhydrase 4"},{"gene":"CA1","source":"DrugCentral","target":"Carbonic anhydrase 1","protein":"Carbonic anhydrase 1"},{"gene":"CA5A","source":"DrugCentral","target":"Carbonic anhydrase 5A, mitochondrial","protein":"Carbonic anhydrase 5A, mitochondrial"},{"gene":"CA6","source":"DrugCentral","target":"Carbonic anhydrase 6","protein":"Carbonic anhydrase 6"},{"gene":"CA2","source":"DrugCentral","target":"Carbonic anhydrase 2","protein":"Carbonic anhydrase 2"},{"gene":"CA14","source":"DrugCentral","target":"Carbonic anhydrase 14","protein":"Carbonic anhydrase 14"}],"modality":"Small Molecule","drugClass":"Thiazide-like Diuretic","explanation":"","oneSentence":"","technicalDetail":"Combipres (Chlortalidone) is a thiazide-like diuretic that inhibits carbonic anhydrase 7, leading to increased sodium and water excretion in the kidneys, resulting in decreased blood volume and pressure."},"commercial":{"launchDate":"1960","_launchSource":"DrugCentral (FDA 1960-04-07, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/625","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Chlortalidone","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chlortalidone","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:35:35.321364","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:00:11.722561+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"quinethazone","drugSlug":"quinethazone","fdaApproval":"1963-04-10","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"metolazone","drugSlug":"metolazone","fdaApproval":"1973-11-27","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"indapamide","drugSlug":"indapamide","fdaApproval":"1983-07-06","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"chlortalidone","indications":{"approved":[{"name":"Edema","source":"DrugCentral","snomedId":267038008,"regulator":"FDA"},{"name":"Hypertensive disorder","source":"DrugCentral","snomedId":38341003,"regulator":"FDA"},{"name":"Peripheral Edema due to Chronic Heart Failure","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults with peripheral edema due to chronic heart failure.","usPrevalence":6200000,"globalPrevalence":64000000,"prevalenceMethod":"curated","prevalenceSource":"ESC Heart Failure, 2023"},{"name":"Pulmonary Edema due to Chronic Heart Failure","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults with pulmonary edema due to chronic heart failure.","usPrevalence":6200000,"globalPrevalence":64000000,"prevalenceMethod":"curated","prevalenceSource":"ESC Heart Failure, 2023"}],"offLabel":[{"name":"Calcium renal calculus","source":"DrugCentral","drugName":"Chlortalidone","evidenceCount":26,"evidenceLevel":"moderate"},{"name":"Diabetes insipidus","source":"DrugCentral","drugName":"Chlortalidone","evidenceCount":14,"evidenceLevel":"moderate"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"quinethazone","brandName":"quinethazone","genericName":"quinethazone","approvalYear":"1963","relationship":"same-class"},{"drugId":"metolazone","brandName":"metolazone","genericName":"metolazone","approvalYear":"1973","relationship":"same-class"},{"drugId":"indapamide","brandName":"indapamide","genericName":"indapamide","approvalYear":"1983","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05293756","phase":"NA","title":"OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)","status":"RECRUITING","sponsor":"Case Western Reserve University","startDate":"2021-02-14","conditions":["Hypertension","Self-Management","Technology","Quality of Life"],"enrollment":208,"completionDate":"2027-05-31"},{"nctId":"NCT06287580","phase":"EARLY_PHASE1","title":"Effects of Antihypertensive Drug Treatment on Brain Blood Flow, Cognition, and Regulation of Nervous System in Older Adults With Hypertension.","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-08-15","conditions":["Essential Hypertension","Older Adults"],"enrollment":27,"completionDate":"2026-02-20"},{"nctId":"NCT06041529","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2023-10-18","conditions":["Essential Hypertension"],"enrollment":198,"completionDate":"2026-02-28"},{"nctId":"NCT05370599","phase":"PHASE2","title":"Hypertension in Young Adults Trial","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2022-04-15","conditions":["Hypertension"],"enrollment":36,"completionDate":"2026-01-07"},{"nctId":"NCT05593055","phase":"PHASE4","title":"Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-08-25","conditions":["Hypertension","Left Ventricular Hypertrophy"],"enrollment":75,"completionDate":"2027-12-31"},{"nctId":"NCT05171686","phase":"PHASE4","title":"Diuretics and Volume Overload in Early CKD","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2023-02-01","conditions":["Chronic Kidney Disease","Hypertension"],"enrollment":49,"completionDate":"2025-10-02"},{"nctId":"NCT02483936","phase":"PHASE3","title":"Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"","conditions":["Arterial Hypertension"],"enrollment":0,"completionDate":""},{"nctId":"NCT02493322","phase":"PHASE3","title":"Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"","conditions":["Essential Arterial Hypertension"],"enrollment":0,"completionDate":""},{"nctId":"NCT07238400","phase":"PHASE2","title":"Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-12-01","conditions":["Hypertension"],"enrollment":90,"completionDate":"2029-03-30"},{"nctId":"NCT07225764","phase":"PHASE4","title":"CaOx Stone Prevention","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2025-10-23","conditions":["Kidney Stones"],"enrollment":80,"completionDate":"2027-06-30"},{"nctId":"NCT04519164","phase":"PHASE4","title":"Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-12-01","conditions":["Metabolic Syndrome","Hypertension","Overweight and Obesity"],"enrollment":79,"completionDate":"2025-09-17"},{"nctId":"NCT02847338","phase":"PHASE4","title":"Comparison of Optimal Hypertension Regimens","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2016-11","conditions":["Hypertension"],"enrollment":940,"completionDate":"2023-10"},{"nctId":"NCT07116863","phase":"PHASE3","title":"A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Kyungdong Pharmaceutical Co., Ltd.","startDate":"2022-06-21","conditions":["Essential Hypertension"],"enrollment":286,"completionDate":"2024-09-13"},{"nctId":"NCT05411991","phase":"PHASE4","title":"Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment","status":"COMPLETED","sponsor":"Vrije Universiteit Brussel","startDate":"2022-06-12","conditions":["Acute Heart Failure","Diuretics Drug Reactions"],"enrollment":107,"completionDate":"2024-07-01"},{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":["Hypertension"],"enrollment":702,"completionDate":"2025-05-01"},{"nctId":"NCT01191450","phase":"PHASE3","title":"Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2011-08","conditions":["Arterial Hypertension"],"enrollment":246,"completionDate":"2013-08"},{"nctId":"NCT06495710","phase":"NA","title":"Arterial Stiffness and Blood Pressure","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-05-01","conditions":["Hypertension","Vascular Stiffness","Aging"],"enrollment":228,"completionDate":"2028-12-31"},{"nctId":"NCT05915286","phase":"PHASE4","title":"Diuretic Use in Hemodialysis Patients With Residual Renal Function","status":"SUSPENDED","sponsor":"University of Alberta","startDate":"2023-05-29","conditions":["End Stage Renal Disease on Dialysis"],"enrollment":34,"completionDate":"2026-02-01"},{"nctId":"NCT04927299","phase":"PHASE3","title":"Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2022-06-30","conditions":["Essential Arterial Hypertension"],"enrollment":163,"completionDate":"2023-09-11"},{"nctId":"NCT06111885","phase":"PHASE2","title":"Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2024-10-01","conditions":["Kidney Stone"],"enrollment":99,"completionDate":"2027-06-30"},{"nctId":"NCT06282549","phase":"","title":"Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2022-06-08","conditions":["Essential Hypertension"],"enrollment":1219,"completionDate":"2027-03-31"},{"nctId":"NCT02620163","phase":"PHASE3","title":"Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2015-12","conditions":["Hypertension"],"enrollment":381,"completionDate":"2016-12"},{"nctId":"NCT03662620","phase":"PHASE1","title":"Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2018-10-05","conditions":["Hypertension"],"enrollment":67,"completionDate":"2018-12-22"},{"nctId":"NCT02185417","phase":"PHASE3","title":"Diuretic Comparison Project","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2016-06-15","conditions":["Hypertension"],"enrollment":20723,"completionDate":"2022-12-29"},{"nctId":"NCT00006294","phase":"","title":"Genetics of Hypertension Associated Treatments (GenHAT)","status":"COMPLETED","sponsor":"Donna Arnett, 257-5678","startDate":"1999-09","conditions":["Cardiovascular Diseases","Heart Diseases","Hypertension","Coronary Disease","Myocardial Infarction"],"enrollment":37939,"completionDate":"2005-08"},{"nctId":"NCT04470830","phase":"","title":"A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea","status":"COMPLETED","sponsor":"Celltrion Pharm, Inc.","startDate":"2019-09-11","conditions":["Essential Hypertension"],"enrollment":718,"completionDate":"2023-05-25"},{"nctId":"NCT02665117","phase":"NA","title":"Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2015-01","conditions":["Hypertension"],"enrollment":61,"completionDate":"2022-11-04"},{"nctId":"NCT05275907","phase":"PHASE4","title":"Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN)","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2022-07-12","conditions":["High Blood Pressure","Liver Transplant","Renal Function Abnormal"],"enrollment":0,"completionDate":"2023-10-04"},{"nctId":"NCT05199129","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2021-11-17","conditions":["Hypertension"],"enrollment":166,"completionDate":"2022-09-14"},{"nctId":"NCT04830449","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2020-10-29","conditions":["Hypertension"],"enrollment":122,"completionDate":"2021-08-24"},{"nctId":"NCT04820907","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2020-10-27","conditions":["Hypertension"],"enrollment":123,"completionDate":"2021-09-30"},{"nctId":"NCT05222191","phase":"PHASE2","title":"Spironolactone in CKD Enabled by Chlorthalidone: PILOT","status":"UNKNOWN","sponsor":"Indiana Institute for Medical Research","startDate":"2022-02-01","conditions":["Renal Insufficiency","Chronic Hypertension"],"enrollment":24,"completionDate":"2023-12-12"},{"nctId":"NCT05976438","phase":"NA","title":"Skin Sodium and Salt Sensitivity of Blood Pressure","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2023-08","conditions":["Hypertension"],"enrollment":60,"completionDate":"2024-12"},{"nctId":"NCT02841280","phase":"PHASE2","title":"Chlorthalidone in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Indiana University","startDate":"2016-07","conditions":["Renal Insufficiency, Chronic","Hypertension"],"enrollment":160,"completionDate":"2021-04"},{"nctId":"NCT02711670","phase":"NA","title":"Night Time Use of Thiazide Diuretics for Improved Reduction in Stone Risk in Stone Formers With Elevated Urine Calcium","status":"COMPLETED","sponsor":"VA New York Harbor Healthcare System","startDate":"2014-02","conditions":["Kidney Stones"],"enrollment":10,"completionDate":"2017-06"},{"nctId":"NCT05580510","phase":"PHASE2,PHASE3","title":"\" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD \"","status":"UNKNOWN","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2023-02-06","conditions":["Congenital Heart Disease","Heart Failure","Heart Failure With Reduced Ejection Fraction"],"enrollment":160,"completionDate":"2024-03-29"},{"nctId":"NCT03666351","phase":"PHASE4","title":"Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-10-18","conditions":["Aortic Stenosis","Aortic Regurgitation","Hypertension","LVM","Left Ventricular Hypertrophy"],"enrollment":128,"completionDate":"2022-07-25"},{"nctId":"NCT05462535","phase":"","title":"An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-02-26","conditions":["Hypertension,Essential"],"enrollment":4785,"completionDate":"2021-07-15"},{"nctId":"NCT00231803","phase":"NA","title":"The Canadian Prevention of Renal and Cardiovascular Endpoints Trial","status":"COMPLETED","sponsor":"Brendan Barrett","startDate":"2005-04","conditions":["Chronic Kidney Disease"],"enrollment":474,"completionDate":"2008-06"},{"nctId":"NCT04192110","phase":"PHASE4","title":"Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD","status":"WITHDRAWN","sponsor":"VA Office of Research and Development","startDate":"2020-08-11","conditions":["Chronic Kidney Disease"],"enrollment":0,"completionDate":"2020-08-11"},{"nctId":"NCT05090449","phase":"PHASE1","title":"Non-interaction Study of Chlorthalidone and Losartan in Fixed Combination, in Healthy Subjects, Under Fasting Conditions","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2019-05-01","conditions":["Healthy"],"enrollment":36,"completionDate":"2020-05-25"},{"nctId":"NCT05077475","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52L in Healthy Volunteers","status":"UNKNOWN","sponsor":"AJU Pharm Co., Ltd.","startDate":"2021-09-24","conditions":["Hypertension"],"enrollment":60,"completionDate":"2022-04-30"},{"nctId":"NCT05077462","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52H in Healthy Volunteers","status":"UNKNOWN","sponsor":"AJU Pharm Co., Ltd.","startDate":"2021-09-17","conditions":["Hypertension"],"enrollment":60,"completionDate":"2022-04-30"},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":["Hypertension","COVID"],"enrollment":22213,"completionDate":"2020-12-31"},{"nctId":"NCT04757532","phase":"PHASE1","title":"Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2020-12-03","conditions":["Healthy Volunteers"],"enrollment":9,"completionDate":"2021-03-10"},{"nctId":"NCT03325114","phase":"PHASE2","title":"Safety and Efficacy of Chlorthalidone in Type 1 Diabetes","status":"TERMINATED","sponsor":"University of Rochester","startDate":"2019-06-28","conditions":["Type 1 Diabetes Mellitus","Hypercalciuria"],"enrollment":1,"completionDate":"2020-06-01"},{"nctId":"NCT03923933","phase":"PHASE2","title":"Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial","status":"COMPLETED","sponsor":"Hospital General de México Dr. Eduardo Liceaga","startDate":"2019-06-18","conditions":["Renal Insufficiency, Chronic"],"enrollment":34,"completionDate":"2019-10-28"},{"nctId":"NCT03006796","phase":"","title":"Observational Study of Azilsartan/Chlorthalidone and Irbesartan/Hydrochlorothiazide in Hypertension and Obesity.","status":"COMPLETED","sponsor":"Russian Heart Failure Society","startDate":"2017-01-16","conditions":["Arterial Hypertension"],"enrollment":94,"completionDate":"2020-03-31"},{"nctId":"NCT04393493","phase":"PHASE2","title":"The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide.","status":"COMPLETED","sponsor":"Hospital Civil de Guadalajara","startDate":"2017-07-01","conditions":["Cardiorenal Syndrome"],"enrollment":80,"completionDate":"2020-04-01"},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":["Hypertension","COVID-19"],"enrollment":2414,"completionDate":"2021-12-01"},{"nctId":"NCT02357004","phase":"NA","title":"Mechanisms of Refractory Hypertension (Carvedilol)","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2015-02","conditions":["Hypertensive"],"enrollment":0,"completionDate":"2020-01-31"},{"nctId":"NCT03928145","phase":"PHASE3","title":"Efficacy of Chlorthalidone and Hydrochlorothiazide Combined With Amiloride on Blood Pressure in Primary Hypertension.","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2019-11-13","conditions":["Hypertension"],"enrollment":84,"completionDate":"2021-07"},{"nctId":"NCT02236520","phase":"PHASE2","title":"Tissue Sodium in Pre-hypertensive Patients","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-09","conditions":["Hypertension"],"enrollment":71,"completionDate":"2018-05-01"},{"nctId":"NCT01973335","phase":"PHASE4","title":"Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure","status":"COMPLETED","sponsor":"Hasselt University","startDate":"2013-11","conditions":["Heart Failure"],"enrollment":34,"completionDate":"2017-10"},{"nctId":"NCT03156634","phase":"NA","title":"A Pilot Study of the Impact of the Patient Activated Learning System (PALS) on Knowledge Acquisition, Recall, and Decision Making","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2017-04-15","conditions":["Patient Education"],"enrollment":118,"completionDate":"2017-12-31"},{"nctId":"NCT00353652","phase":"PHASE4","title":"Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2005-01","conditions":["Hypertension"],"enrollment":166,"completionDate":"2013-01"},{"nctId":"NCT01083017","phase":"","title":"Resistant Arterial Hypertension Cohort Study","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2011-04","conditions":["Hypertension","Essential Hypertension","Resistant Hypertension"],"enrollment":74,"completionDate":"2017-05"},{"nctId":"NCT02814552","phase":"NA","title":"OPTImizing Precision of Hypertension Care to Maximize Blood Pressure Control Pilot (OPTI-BP Pilot)","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-06-18","conditions":["High Blood Pressure"],"enrollment":47,"completionDate":"2018-06-30"},{"nctId":"NCT03560804","phase":"NA","title":"Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect of Two Drugs","status":"COMPLETED","sponsor":"AHEPA University Hospital","startDate":"2014-11-10","conditions":["Arterial Stiffness","Ambulatory Blood Pressure Monitoring"],"enrollment":60,"completionDate":"2017-09-15"},{"nctId":"NCT02896621","phase":"PHASE3","title":"Effect of Antihypertensive Agents on Diastolic Function in Patients With Sleep Apnea","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2014-12-07","conditions":["Hypertension","Sleep Apnea"],"enrollment":69,"completionDate":"2017-02-14"},{"nctId":"NCT01203852","phase":"PHASE4","title":"Pharmacogenomic Evaluation of Antihypertensive Responses 2","status":"COMPLETED","sponsor":"University of Florida","startDate":"2010-08","conditions":["Hypertension"],"enrollment":839,"completionDate":"2014-04"},{"nctId":"NCT02502981","phase":"PHASE4","title":"Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD","status":"UNKNOWN","sponsor":"University Hospital Birmingham","startDate":"2014-06","conditions":["Renal Insufficiency, Chronic","Cardio-Renal Syndrome"],"enrollment":154,"completionDate":"2018-05"},{"nctId":"NCT02591628","phase":"NA","title":"Treatment of Hypertension In Adults With ThiaZIDES: Pragmatic Trial Pilot Study","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2015-08","conditions":["Hypertension"],"enrollment":2027,"completionDate":"2017-07"},{"nctId":"NCT01748123","phase":"PHASE4","title":"EBMtrialcentral- Comparing Initial Diuretic Therapies Using a Collaborative Network","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2016-08","conditions":["Hypertension"],"enrollment":0,"completionDate":"2018-06"},{"nctId":"NCT03226340","phase":"PHASE4","title":"S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-12-02","conditions":["Essential Hypertension"],"enrollment":170,"completionDate":"2018-03-31"},{"nctId":"NCT02644395","phase":"PHASE3","title":"Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2013-01-18","conditions":["Hypertension","Kidney Transplantation"],"enrollment":49,"completionDate":"2016-12-19"},{"nctId":"NCT02030314","phase":"PHASE4","title":"The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone","status":"WITHDRAWN","sponsor":"Virginia Commonwealth University","startDate":"2013-07","conditions":["Resistant Hypertension in Kidney Transplant Patients"],"enrollment":0,"completionDate":"2017-04-12"},{"nctId":"NCT02121041","phase":"NA","title":"Ambulatory vs Office BP Management Usual Care for Diagnosing and Managing Hypertension: A Pilot Study","status":"COMPLETED","sponsor":"Anthony J Viera, MD, MPH","startDate":"2014-05","conditions":["Hypertension"],"enrollment":28,"completionDate":"2016-07"},{"nctId":"NCT02232880","phase":"PHASE2","title":"Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2014-08","conditions":["Hypertension"],"enrollment":1,"completionDate":"2015-06"},{"nctId":"NCT02521246","phase":"PHASE3","title":"Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"2016-11","conditions":["Essential Arterial Hypertension"],"enrollment":0,"completionDate":"2017-08"},{"nctId":"NCT02521233","phase":"PHASE3","title":"Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"2016-11","conditions":["Essential Arterial Hypertension"],"enrollment":0,"completionDate":"2017-08"},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":["Atherosclerosis","Cardiovascular Diseases","Hypercholesterolemia","Hypertension","Diabetes Mellitus, Type 2","Diabetes Mellitus","Coronary Disease"],"enrollment":10251,"completionDate":"2012-12"},{"nctId":"NCT02916602","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2015-04","conditions":["Hypertension"],"enrollment":340,"completionDate":"2016-09"},{"nctId":"NCT00000542","phase":"PHASE3","title":"Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1993-08","conditions":["Cardiovascular Diseases","Coronary Disease","Diabetes Mellitus","Heart Diseases","Hypercholesterolemia","Hypertension","Myocardial Infarction","Myocardial Ischemia","Heart Failure"],"enrollment":0,"completionDate":"2002-03"},{"nctId":"NCT01896661","phase":"PHASE3","title":"Effect of Antihypertensive Agents Over Sleep Apnea","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2014-12","conditions":["Hypertension","Obstructive Sleep Apnea"],"enrollment":53,"completionDate":"2016-02"},{"nctId":"NCT01750294","phase":"PHASE4","title":"A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD","status":"COMPLETED","sponsor":"Indiana University","startDate":"2012-08","conditions":["Chronic Kidney Disease","Poorly-Controlled Hypertension"],"enrollment":14,"completionDate":"2013-08"},{"nctId":"NCT00000514","phase":"PHASE3","title":"Systolic Hypertension in the Elderly Program (SHEP)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1984-06","conditions":["Cardiovascular Diseases","Cerebrovascular Disorders","Heart Diseases","Hypertension"],"enrollment":0,"completionDate":"1996-10"},{"nctId":"NCT00000522","phase":"PHASE2","title":"Treatment of Mild Hypertension Study (TOMHS)","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"1985-08","conditions":["Cardiovascular Diseases","Heart Diseases","Hypertension","Vascular Diseases"],"enrollment":0,"completionDate":"1994-05"},{"nctId":"NCT01850160","phase":"PHASE3","title":"Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension","status":"COMPLETED","sponsor":"Farma de Colombia SA","startDate":"2013-04","conditions":["Hypertension"],"enrollment":124,"completionDate":"2015-05"},{"nctId":"NCT02100462","phase":"PHASE4","title":"Chlorthalidone and HCTZ Impacts on Platelet Activation","status":"UNKNOWN","sponsor":"Creighton University","startDate":"2014-03","conditions":["Hypertension"],"enrollment":30,"completionDate":"2016-12"},{"nctId":"NCT02496910","phase":"PHASE1","title":"PK Study of YH22162 FDC Compared to Combination of Twynsta and Hygroton","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2015-06","conditions":["Hypertension"],"enrollment":180,"completionDate":"2015-09"},{"nctId":"NCT02387554","phase":"PHASE1","title":"Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2014-08","conditions":["Hypertension(HTN)"],"enrollment":33,"completionDate":"2014-10"},{"nctId":"NCT01822860","phase":"PHASE4","title":"Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function","status":"WITHDRAWN","sponsor":"Creighton University","startDate":"2013-03","conditions":["Hypertension"],"enrollment":0,"completionDate":"2015-02"},{"nctId":"NCT00971165","phase":"PHASE3","title":"Diuretics and Angiotensin-Receptor Blocker Agents in Patients With Stage I Hypertension","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2010-07","conditions":["Hypertension","Cardiovascular Disease"],"enrollment":655,"completionDate":"2014-09"},{"nctId":"NCT00970931","phase":"PHASE3","title":"Hypertension Prevention in Pre-Hypertensive Individuals","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2010-07","conditions":["Pre-hypertension","Hypertension","Cardiovascular Disease"],"enrollment":730,"completionDate":"2014-09"},{"nctId":"NCT01235377","phase":"PHASE4","title":"Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study","status":"COMPLETED","sponsor":"VA Pharmacy Benefits Management Strategic Healthcare Group","startDate":"2011-09","conditions":["Hypertension"],"enrollment":20,"completionDate":"2014-02"},{"nctId":"NCT02152969","phase":"PHASE1","title":"Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2014-05","conditions":["Hypertension"],"enrollment":66,"completionDate":"2014-11"},{"nctId":"NCT01456169","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-10","conditions":["Essential Hypertension"],"enrollment":507,"completionDate":"2013-01"},{"nctId":"NCT00563901","phase":"","title":"Analyzing How Genetics May Affect Response to High Blood Pressure Medications","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2000-09","conditions":["Hypertension","Coronary Disease","Cerebrovascular Accident"],"enrollment":37939,"completionDate":"2004-05"},{"nctId":"NCT01806363","phase":"PHASE1","title":"Pharmacokinetic Interactions and Safety Study of Telmisartan and Chlorthalidone","status":"COMPLETED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2012-11","conditions":["Hypertension"],"enrollment":60,"completionDate":"2013-06"},{"nctId":"NCT01309828","phase":"PHASE3","title":"Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-03","conditions":["Safety"],"enrollment":153,"completionDate":"2012-10"},{"nctId":"NCT00000499","phase":"PHASE2","title":"Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1980-09","conditions":["Cardiovascular Diseases","Heart Diseases","Hypertension","Vascular Diseases"],"enrollment":0,"completionDate":"1983-05"},{"nctId":"NCT00000513","phase":"PHASE3","title":"Trial of Antihypertensive Intervention Management","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1984-04","conditions":["Cardiovascular Diseases","Heart Diseases","Hypertension","Vascular Diseases"],"enrollment":0,"completionDate":"1994-11"},{"nctId":"NCT00000525","phase":"PHASE3","title":"Diuretics, Hypertension, and Arrhythmias Clinical Trial","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"1986-07","conditions":["Cardiovascular Diseases","Death, Sudden, Cardiac","Heart Arrest","Heart Diseases","Hypertension"],"enrollment":233,"completionDate":""},{"nctId":"NCT00241839","phase":"PHASE3","title":"Uric Acid and Hypertension in African Americans","status":"COMPLETED","sponsor":"University of Florida","startDate":"2005-08","conditions":["Cardiovascular Diseases","Heart Diseases","Hypertension"],"enrollment":150,"completionDate":"2011-05"},{"nctId":"NCT01368536","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-05","conditions":["Hypertension","Stage 2 Hypertension","Diabetes"],"enrollment":975,"completionDate":"2012-02"},{"nctId":"NCT00996281","phase":"PHASE3","title":"Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-10","conditions":["Essential Hypertension"],"enrollment":837,"completionDate":"2011-11"},{"nctId":"NCT00846365","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-03","conditions":["Essential Hypertension"],"enrollment":1085,"completionDate":"2010-06"},{"nctId":"NCT00818883","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-02","conditions":["Essential Hypertension"],"enrollment":609,"completionDate":"2009-11"},{"nctId":"NCT00847626","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-01","conditions":["Hypertension"],"enrollment":1711,"completionDate":"2010-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"ATENOLOL AND CHLORTHALIDONE"},{"form":"TABLET","route":"ORAL","productName":"Atenolol and Chlorthalidone"},{"form":"TABLET","route":"ORAL","productName":"CHLORTHALIDONE"},{"form":"TABLET","route":"ORAL","productName":"CHLORTHALIDONECHLORTHALIDONE"},{"form":"TABLET","route":"ORAL","productName":"Chlorthalidone"},{"form":"TABLET","route":"ORAL","productName":"Edarbyclor"},{"form":"TABLET","route":"ORAL","productName":"TENORETIC"},{"form":"TABLET","route":"ORAL","productName":"Thalitone"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146240","MMSL":"4364","NDDF":"002309","UNII":"Q0MQD1073Q","VUID":"4017887","CHEBI":"CHEBI:3654","VANDF":"4017887","INN_ID":"1125","RXNORM":"2409","UMLSCUI":"C0008294","chemblId":"CHEMBL1055","ChEMBL_ID":"CHEMBL1055","KEGG_DRUG":"D00272","DRUGBANK_ID":"DB00310","PDB_CHEM_ID":" KLT","PUBCHEM_CID":"2732","SNOMEDCT_US":"387324004","IUPHAR_LIGAND_ID":"7147","MESH_DESCRIPTOR_UI":"D002752"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"36.0 hours","clearance":"1.5 mL/min/kg","fractionUnbound":"0.24%","volumeOfDistribution":"3.9 L/kg"},"publicationCount":90,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C03BA04","allCodes":["C03BA04","C03BB04","C03EA06"]},"biosimilarFilings":[],"recentPublications":[{"date":"2006","pmid":"30000622","title":"Chlorthalidone.","journal":""},{"date":"2024 Oct","pmid":"39484134","title":"Efficacy and Safety of Chlortalidone and Hydrochlorothiazide in Prevention of Cardiovascular Diseases.","journal":"Reviews in cardiovascular medicine"},{"date":"2024 Nov 15","pmid":"39243877","title":"Prevention of Heart Failure in Hypertension-the Role of Coronary Heart Disease Events Treated With Versus Without Revascularization: The ALLHAT Study.","journal":"The American journal of cardiology"},{"date":"2024 Aug 15","pmid":"39067499","title":"Knowing the minimal detectable dose can facilitate the interpretation of a hair test result: Case example with chlortalidone.","journal":"Clinica chimica acta; international journal of clinical chemistry"},{"date":"2024 May 28","pmid":"38743262","title":"Cu/Co Bimetallic Carbon Catalyst as a Highly Efficient Promoter for Reactive Dyes Degradation with PMS.","journal":"Langmuir : the ACS journal of surfaces and colloids"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"University Hospital Birmingham","companyId":"university-hospital-birmingham","modality":"Small molecule","firstApprovalDate":"1960","aiSummary":"","enrichmentLevel":3,"visitCount":2,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1960-04-07T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"7572920","territory":"US","patent_type":null,"expiry_date":"2025-01-07T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7157584","territory":"US","patent_type":null,"expiry_date":"2025-05-22T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9066936","territory":"US","patent_type":null,"expiry_date":"2028-03-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9169238","territory":"US","patent_type":null,"expiry_date":"2030-02-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9387249","territory":"US","patent_type":null,"expiry_date":"2031-07-01T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:00:11.722561+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}